A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)
← catalyst calendarNCT07266558 · readout in 301 d
Sponsored by ModernaTX, Inc. (industry) · MRNA — their whole pipeline →.
Phase
Phase 4
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Triple · Prevention
Enrollment
30,000estimated
Sites
150
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-11-26 | actual | When the study began enrolling |
| Primary completion | 2027-06-16 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-06-16 | estimated | The whole study's end, after follow-up |
| First posted | 2025-12-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- SARS-CoV-2
Interventions
- Biological: mRNA-1273
- Biological: mRNA-1283
- Biological: Placebo
Primary outcomes
what the primary-completion date above is the date OFVE of mRNA-1273 (Variant Formulation) to Prevent the First Event of Symptomatic COVID-19 after Study Injection
measured Day 1 through Day 181
Vaccine Efficacy (VE) of mRNA-1283 (Variant Formulation) to Prevent the First Event of Symptomatic COVID-19 after Study Injection
measured Day 1 through Day 181
Number of Participants with Unsolicited Adverse Events (AEs)
measured Day 1 through Day 28
Number of Participants with Serious AEs (SAEs), Medically Attended AEs (MAAEs), AEs of Special Interest (AESIs), and AEs Leading to Discontinuation
measured Day 1 through Day 181
Permalink · MRNA's whole pipeline · Catalyst calendar · Every registered study · What changed